Cargando…

SGLT2 Inhibitors: Slowing of Chronic Kidney Disease Progression in Type 2 Diabetes

Diabetic kidney disease (DKD) is a topic of increasing concern among clinicians involved in the management of type 2 diabetes mellitus (T2DM). It is a progressive and costly complication associated with increased risk of adverse cardiovascular (CV) and renal outcomes and mortality. Ongoing monitorin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wheeler, David C., James, June, Patel, Dipesh, Viljoen, Adie, Ali, Amar, Evans, Marc, Fernando, Kevin, Hicks, Debbie, Milne, Nicola, Newland-Jones, Philip, Wilding, John
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7524028/ https://www.ncbi.nlm.nih.gov/pubmed/32996085 http://dx.doi.org/10.1007/s13300-020-00930-x

Ejemplares similares

SGLT2 Inhibitors in Type 2 Diabetes Management: Key Evidence and Implications for Clinical Practice
por: Wilding, John, et al.
Publicado: (2018)

SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c—Translating Evidence into Practice
por: Ali, Amar, et al.
Publicado: (2019)

Correction to: SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c—Translating Evidence into Practice
por: Ali, Amar, et al.
Publicado: (2019)

The Place and Value of Sodium-Glucose Cotransporter 2 Inhibitors in the Evolving Treatment Paradigm for Type 2 Diabetes Mellitus: A Narrative Review
por: Wilding, John P. H., et al.
Publicado: (2022)

Optimising the Benefits of SGLT2 Inhibitors for Type 1 Diabetes
por: Evans, Marc, et al.
Publicado: (2019)

Glucagon-Like Peptide 1 Receptor Agonist Usage in Type 2 Diabetes in Primary Care for the UK and Beyond: A Narrative Review
por: Fernando, Kevin, et al.
Publicado: (2021)

SGLT2 inhibition slows tumor growth in mice by reversing hyperinsulinemia
por: Nasiri, Ali R., et al.
Publicado: (2019)

Defining the Role of SGLT2 Inhibitors in Primary Care: Time to Think Differently
por: Evans, Marc, et al.
Publicado: (2022)

Risk Prediction of the Diabetes Missing Million: Identifying Individuals at High Risk of Diabetes and Related Complications
por: Evans, Marc, et al.
Publicado: (2020)

Antioxidant Roles of SGLT2 Inhibitors in the Kidney
por: Llorens-Cebrià, Carmen, et al.
Publicado: (2022)

Glucagon-Like Peptide 1 Therapy: From Discovery to Type 2 Diabetes and Beyond
por: Viljoen, Adie, et al.
Publicado: (2023)

SGLT2 Inhibitors and Kidney Outcomes in Patients with Chronic Kidney Disease
por: Kanduri, Swetha R., et al.
Publicado: (2020)

EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors
por: Fernández-Fernandez, Beatriz, et al.
Publicado: (2023)

The expanding role of SGLT2 inhibitors beyond glucose-lowering to cardiorenal protection
por: Brown, Emily, et al.
Publicado: (2021)

Can SGLT2 inhibitors answer unmet therapeutic needs in chronic kidney disease?
por: De Nicola, Luca, et al.
Publicado: (2022)

SGLT2 and cancer
por: Wright, Ernest M.
Publicado: (2020)

Meeting the Challenge of Virtual Diabetes Care: A Consensus Viewpoint on the Positioning and Value of Oral Semaglutide in Routine Clinical Practice
por: Evans, Marc, et al.
Publicado: (2022)

SGLT2 Inhibitors in Diabetic and Non-Diabetic Chronic Kidney Disease
por: Podestà, Manuel Alfredo, et al.
Publicado: (2023)

Role and mechanisms of SGLT-2 inhibitors in the treatment of diabetic kidney disease
por: Dai, Zhi-Cheng, et al.
Publicado: (2023)

The Impact of SGLT2 Inhibitors in the Heart and Kidneys Regardless of Diabetes Status
por: Matthews, Jennifer, et al.
Publicado: (2023)

Optimal use of SGLT2 inhibitors in diabetic kidney transplant recipients
por: Pham, Phuong-Thu T., et al.
Publicado: (2022)

Safety and efficacy of laropiprant and extended-release niacin combination in the management of mixed dyslipidemias and primary hypercholesterolemia
por: Viljoen, Adie, et al.
Publicado: (2010)

Safety and efficacy of rosiglitazone in the elderly diabetic patient
por: Viljoen, Adie, et al.
Publicado: (2009)

Preventing major adverse cardiovascular events by SGLT-2 inhibition in patients with type 2 diabetes: the role of kidney
por: Giugliano, Dario, et al.
Publicado: (2020)

Nephroprotection by SGLT2 Inhibition: Back to the Future?
por: De Nicola, Luca, et al.
Publicado: (2020)

Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2
por: Ghezzi, Chiara, et al.
Publicado: (2018)

Dual SGLT-1 and SGLT-2 inhibition improves left atrial dysfunction in HFpEF
por: Bode, David, et al.
Publicado: (2021)

SGLT2 Inhibitors and the Risk of Hospitalization for Fournier’s Gangrene: A Nested Case–Control Study
por: Wang, Tongtong, et al.
Publicado: (2020)

Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease
por: Bailey, Clifford J., et al.
Publicado: (2022)

SGLT2 Inhibitors in Chronic Kidney Disease: From Mechanisms to Clinical Practice
por: Skrabic, Roko, et al.
Publicado: (2022)

Digging deep into cells to find mechanisms of kidney protection by SGLT2 inhibitors
por: Tuttle, Katherine R.
Publicado: (2023)

Cardiovascular outcomes and safety of SGLT2 inhibitors in chronic kidney disease patients
por: Chen, Xiutian, et al.
Publicado: (2023)

Modeling the renoprotective mechanisms of SGLT2 inhibition in hypertensive chronic kidney disease
por: Clemmer, John S., et al.
Publicado: (2023)

Novel natural and synthetic inhibitors of solute carriers SGLT1 and SGLT2
por: Oranje, Paul, et al.
Publicado: (2019)

Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor: In the heart of the problem
por: Vallianou, Natalia G., et al.
Publicado: (2021)

Plasma Levels of Middle Molecules to Estimate Residual Kidney Function in Haemodialysis without Urine Collection
por: Vilar, Enric, et al.
Publicado: (2015)

Differential effect of canagliflozin, a sodium–glucose cotransporter 2 (SGLT2) inhibitor, on slow and fast skeletal muscles from nondiabetic mice
por: Otsuka, Hiroko, et al.
Publicado: (2022)

SGLT2 Inhibitors: Nephroprotective Efficacy and Side Effects
por: Garofalo, Carlo, et al.
Publicado: (2019)

Mechanistic evaluation of the inhibitory effect of four SGLT-2 inhibitors on SGLT 1 and SGLT 2 using physiologically based pharmacokinetic (PBPK) modeling approaches
por: Zhang, Yu, et al.
Publicado: (2023)

Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
por: Wicik, Zofia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_q7o2tc4r80ks6o0uajkhlpj87q